Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motesanib + Ixabepilone + Capecitabine in Metastatic Breast Cancer
NCT01349088Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of motesanib in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Dec 2013; status: withdrawn.
02
Drugs
motesanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01349088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349088.